Mirae Asset Global Investments Co. Ltd. Purchases 10,078 Shares of Edwards Lifesciences Corporation $EW

Mirae Asset Global Investments Co. Ltd. boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 13.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 86,235 shares of the medical research company’s stock after purchasing an additional 10,078 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $6,706,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Norges Bank bought a new position in Edwards Lifesciences in the 2nd quarter worth about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares during the last quarter. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 57,824 shares of company stock worth $4,863,323. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $81.28 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The stock has a market cap of $47.17 billion, a price-to-earnings ratio of 35.04, a PEG ratio of 3.14 and a beta of 0.95. The company’s 50 day moving average is $84.76 and its two-hundred day moving average is $80.99.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on EW shares. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Mizuho lifted their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Finally, TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.82.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.